No Data
Shanghai Shyndec Pharmaceutical (600420.SH) plans to have some Pharmaceuticals selected for the tenth batch of national centralized pharmaceutical procurement.
Shanghai Shyndec Pharmaceutical (600420.SH) announced that on December 12, 2024, the company and some of its subsidiaries...
Shanghai Shyndec Pharmaceutical (600420.SH): Plans to be selected for the 10th batch of national Pharmaceutical centralized procurement.
On December 13, Gelonghui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that on December 12, 2024, the company and some of its subsidiaries participated in the bidding for the 10th batch of national centralized pharmaceutical procurement organized by the National Drug Procurement Office (referred to as the Unified Procurement Office), with some pharmaceuticals from its subsidiaries intended to be selected in this centralized procurement.
Shyndec Pharmaceutical Unit Gets Nod to Register Cefpodoxime Proxetil Tablets
Shanghai Shyndec Pharmaceutical (600420.SH): Cefoperazone acetate tablets have obtained a Pharmaceutical registration certificate.
On December 11, Guolonghui reported that Shanghai Shyndec Pharmaceutical (600420.SH) announced that its holding subsidiary, China National Pharmaceutical Group Zhijun (Shenzhen) Pharmaceutical Co., Ltd., received the drug registration certificate for Cefoperazone Ester Tablets approved and issued by the National Medical Products Administration. Cefoperazone Ester Tablets are oral third-generation cephalosporin antibiotics, effective against both Gram-positive and Gram-negative bacteria. They are used to treat upper respiratory infections, lower respiratory infections, uncomplicated urinary tract infections, uncomplicated skin and soft tissue infections, acute uncomplicated gonococcal urethritis and cervicitis, and perianal infections caused by Neisseria gonorrhoeae, among others.
Shyndec Pharma Unit's Codeine Phosphate Included in China's Listing of Chemical Raw Materials
Shanghai Shyndec Pharmaceutical (600420.SH) subsidiary's phosphoric acid codeine active pharmaceutical ingredient obtained approval for marketing application.
Shanghai shyndec pharmaceutical (600420.SH) announced that recently, its wholly-owned subsidiary China National Pharmaceutical Group Industrial Co., Ltd. (...)
No Data
